NRX Pharmaceuticals NRXP
NASDAQ NRXP
$2.85 -0.07 (-2.40%)
At close: Oct 1, 2026 · 4:00 PM EDT

NRX Pharmaceuticals (NRXP) EBIT Margin (2025 - 2026)

Updated

NRX Pharmaceuticals (NRXP) recorded EBIT Margin of -590.83% in Q2 2026, down 159.74 percentage points from the prior quarter.

Analysis

NRX Pharmaceuticals (NRXP) EBIT Margin (2025 - 2026) Analysis & Trends

On a TTM basis, NRX Pharmaceuticals' EBIT Margin came in at -580.71% as of Jun 30, 2026; for FY2025, it came in at -1324.41%.

  • Quarterly EBIT Margin has ranged from -1662.81% in Q3 2025 to -431.09% in Q1 2026 over the past five years.
  • Per Business Quant, the preceding three quarters came in at -431.09% (Q1 2026), -470.40% (Q4 2025) and -1662.81% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 28.21%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 37.86%
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -3.52%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 32.97%
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 20.57%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 34.95%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -133.21%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 28.37%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 37.40%
10 NRX Pharmaceuticals 126.02 Mn 77.61 Mn 426,000.00 -590.83%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -590.83%
Mar 31, 2026 -431.09%
Dec 31, 2025 -470.40%
Sep 30, 2025 -1,662.81%
API Access

NRX Pharmaceuticals EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=NRXP&period=max&api_key=YOUR_API_KEY